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Background. Tenofovir disoproxil fumarate (TDF) has been linked to renal impairment, but the extent to which
this impairment is reversible is unclear. We aimed to investigate the reversibility of renal decline during TDF therapy.
Methods. Cox proportional hazards models assessed factors associated with discontinuing TDF in those with an
exposure duration of >6 months. In those who discontinued TDF therapy, linear piecewise regression models esti-
mated glomerular ﬁltration rate (eGFR) slopes before initiation of, during, and after discontinuation of TDF therapy.
Factors associated with not achieving eGFR recovery 6 months after discontinuing TDF were assessed using multi-
variable logistic regression.
Results. We observed declines in the eGFR during TDF exposure (mean slopes, −15.7 mL/minute/1.73 m2/year
[95% conﬁdence interval {CI}, −20.5 to −10.9] during the ﬁrst 3 months and −3.1 mL/minute/1.73 m2/year [95%
CI, −4.6 to −1.7] thereafter) and evidence of eGFR increases following discontinuation of TDF therapy (mean slopes,
12.5 mL/minute/1.73 m2/year [95% CI, 8.9–16.1] during the ﬁrst 3 months and 0.8 mL/minute/1.73 m2/year [95% CI,
.1–1.5] thereafter). Following TDF discontinuation, 38.6% of patients with a decline in the eGFR did not experience
recovery. A higher eGFR at baseline, a lower eGFR after discontinuation of TDF therapy, and more-prolonged exposure
to TDF were associated with an increased risk of incomplete recovery 6 months after discontinuation of TDF therapy.
Conclusions. This study shows that a decline in the eGFR during TDF therapy was not fully reversible in one
third of patients and suggests that prolonged TDF exposure at a low eGFR should be avoided.
Keywords. tenofovir; highly active antiretroviral therapy; eGFR; eGFR slopes; renal function; kidney.
Tenofovir disoproxil fumarate (TDF) is a widely used
component of combination antiretroviral therapy
(cART) [1–3]. Although clinical trials data indicate a
low incidence of serious renal adverse effects [4–6],
cohort studies have linked TDF use to a decreasing
estimated glomerular ﬁltration rate (eGFR) [7], an
accelerated decrease in the eGFR [8], proximal tubular
dysfunction [9, 10], proteinuria [11], chronic kidney dis-
ease (CKD) [12–14], and increased mortality [15].
Scherzer et al [12] evaluated the effects of TDF
exposure on renal outcomes in 10 000 human immu-
nodeﬁciency virus (HIV)–infected treatment-naive
patients and found that each year of cumulative expo-
sure was associated with a 30% increase in the risk of
proteinuria, an 11% increase in the risk of a rapid decline
in the eGFR (deﬁned as >3 mL/minute/1.73 m2/year),
and a 33% increase in the risk of developing CKD.
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The authors suggest that the effect of TDF therapy was not fully
reversible after discontinuation.
Studies exploring the reversibility of renal function decline
following discontinuation of TDF therapy have focused on in-
dividuals stopping because of toxicity [16–20] but were small in
size with inconclusive outcomes. Wever et al [20] and Yoshino
et al [21] studied predominantly HIV-positive men who discon-
tinued TDF therapy for incident CKD or a low eGFR (median,
48.3 mL/minute/1.73 m2 [interquartile range {IQR}, 45.3–54.3])
and found that only 42% of 45 patients recovered their baseline
eGFR. The majority of individuals had impaired renal function
at the start of TDF exposure, and some continued to experience
a decline in the eGFR following discontinuation of TDF thera-
py. Bonjoch et al [22] looked at individuals with normal renal
function at baseline who discontinued treatment because of tox-
icity and found that the eGFR in 59% returned to normal.
There are few studies in which changes in renal function with
TDF therapy were investigated using eGFR slopes, and of those
that did, none considered the rate of renal decline before TDF
exposure [23]. Faﬁn et al [24] studied the evolution of eGFR in
patients with CKD and observed that TDF exposure was asso-
ciated with a decline in the eGFR and that longer TDF exposure
was associated with a lower eGFR. Kalayjian et al [25] examined
eGFR slopes before and after initial cART exposure. Although
there remained an overall decline in the eGFR during cART, this
was modest and slower than that before cART initiation (0.81
mL/minute/1.73 m2/year [95% conﬁdence interval [CI], 0.03–
1.59]; P = .02). In addition, when eGFR slopes were stratiﬁed
by regimen, a signiﬁcant improvement was seen in those for
whom TDF was coadministered with a protease inhibitor (PI).
Our aim was to evaluate changes in renal function before ini-
tiation of, during, and after discontinuation of TDF therapy,
using eGFR slopes in HIV-positive individuals who discontin-
ued TDF therapy. We also examined the extent to which the de-
cline in eGFR associated with TDF was reversible following
discontinuation of TDF therapy, accounting for preexisting
renal decline, and the factors associated with incomplete
eGFR reversibility.
METHODS
Patients
Data were obtained from the United Kingdom Collaborative
HIV Cohort (UK CHIC) Study, which collates routinely collect-
ed data on HIV-positive individuals >16 years age from several
of the largest HIV clinics in the United Kingdom [26]. The
study was approved by a multicenter research ethics committee
and by local ethics committees and does not require informed
consent. Data up to December 2010 were available from 9 cen-
ters that routinely provided creatinine measurements. Eligible
subjects were exposed to TDF for a period of at least 6 months.
The ﬁrst available episode of TDF treatment that lasted >6
months was used. Patients who discontinued TDF therapy
were included in the analysis of eGFR slopes and those whose
eGFR declined during TDF therapy were analyzed for recovery.
For the analysis of eGFR slopes and recovery, individuals were
required to have at least 6 months of follow-up and ≥3 serum
creatinine measurements before initiation of, during, and after
discontinuation of TDF therapy.
Variable Deﬁnitions
Serum creatinine measurements were converted to eGFRs, using
the CKD Epidemiology Collaboration equation [27, 28]. When a
patient’s eGFR slope before initiation of TDF therapy was <0, this
indicated a preexisting decline in the eGFR. Recovery was then
deﬁned differently for those with and those without evidence of
a preexisting decline in the eGFR. For patients in whom there was
a preexisting decline, we predicted the eGFR at the time of TDF
therapy discontinuation by using the eGFR slope before initiation
of TDF therapy and the duration of TDF exposure, and recovery
was deﬁned at the ﬁrst of 2 consecutive eGFRs within 5% of this
predicted eGFR. For those without evidence of a decline before
TDF exposure, recovery was deﬁned at the ﬁrst of 2 consecutive
eGFRs within 5% of the eGFR at the time of TDF initiation (base-
line). Sensitivity analyses allowed for greater within-patient vari-
ability by changing this 5% cutoff to 10% and 15%. Anyone who
did not experience recovery in the eGFR was deemed to have had
an incomplete recovery. A normal eGFR was deﬁned as an eGFR
of ≥90 mL/minute/1.73 m2/year.
Statistical Analysis
Factors associated with discontinuation of TDF after 6 months
were investigated with Cox proportional hazards models. Time-
dependent covariates considered were age, AIDS-deﬁning events,
CD4+ T-cell count, viral load, ART regimen (nonnucleoside re-
verse-transcriptase inhibitor [NNRTI] based; PI based, including
atazanavir; PI based, not including atazanavir; and other regi-
mens), eGFR, hepatitis B status, and hepatitis C status. Time-
independent covariates included sex, ethnicity, route of HIV
exposure, previous ART exposure (ART naive, experienced
with no prior TDF exposure, and experienced with prior TDF
exposure) and calendar year when TDF therapy was started.
All covariates with a P value of < .1 in the univariable analysis
were considered for entry into the multivariable model.
In subjects who discontinued TDF treatment, changes in the
eGFR before initiation of, during, and after discontinuation of
TDF therapy were investigated. Separate piecewise linear regres-
sion models were ﬁtted for each patient to estimate eGFR slopes
in the 3 periods. eGFR slopes during and after TDF exposure
were split into 2 periods: ≤3 months and >3 months (Supple-
mentary Figure 1). This was done to separate any effect of resid-
ual drug exposure and early tubular creatinine secretion from
longer-term slope estimates. Slopes were stratiﬁed according
to baseline eGFRs of <60, 60–89, and ≥90 mL/minute/1.73 m2.
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Figure 1. Flow of patient selection for this analysis.
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Factors associated with incomplete eGFR recovery 6 months
after discontinuation of TDF therapy were assessed using logis-
tic regression. Factors considered for inclusion in the model
were eGFR at start and discontinuation of TDF therapy, time
exposed to TDF, CD4+ T-cell count and HIV load at start
and discontinuation of TDF therapy, being ART naive at start
of TDF therapy, cART regimen (PI vs NNRTI vs other), and
demographic characteristics. Covariates considered for entry
in the multivariable model were chosen a priori as possible con-
founders or had a P value of < .1 in univariable analyses. Anal-
yses were stratiﬁed by baseline eGFR to determine whether
starting or stopping TDF with an eGFR within the normal
range inﬂuenced recovery. Sensitivity analyses considered factors
associated with incomplete recovery out to 12 and 24months. We
also assessed recovery in those most likely to have discontinued
TDF treatment because of toxicity by excluding those with a de-
tectable viral load at the time TDF therapy was discontinued. All
analyses were performed in SAS (version 9.3).
RESULTS
In total, 13 007 were included in the analysis (Figure 1). Baseline
characteristics of these individuals are described in Table 1. The
majority were white men who acquired HIV through sex with
other men; 34.4% were ART naive at the time TDF therapy was
started.
Factors Associated With Discontinuation of TDF Therapy
A total 3088 (23.7%) patients discontinued TDF therapy, for an
incidence rate of 7.3 cases/100 person-years (95% CI, 7.0%–
7.5%). The median exposure time was 2.6 years (IQR, 1.5–4.8
years). A decline in the eGFR during TDF exposure was expe-
rienced by 1882 individuals (61%) who discontinued TDF therapy;
56.3%, 21.0%, 12.3%, and 10.3% discontinued TDF therapy with
an eGFR of ≥90, 75–89, 60–74, and <60 mL/minute/1.73 m2,
respectively, compared with 65.6%, 22.2%, 9.8%, and 2.4% in
the same eGFR thresholds at baseline. Of 2906 individuals
with a viral load measurement before stopping TDF therapy,
2049 (70.5%) had an undetectable viral load. A higher viral
load (hazard ratio [HR], 1.6 per 1 log10 increase [95% CI,
1.55–1.66]) and a lower eGFR (eGFR 60–74 mL/minute/1.73 m2:
HR, 1.21 [95% CI, 1.08–1.25]; eGFR < 60 mL/minute/1.73 m2:
HR, 3.90 [95% CI, 3.45–4.42]) were associated with an in-
creased risk of TDF discontinuation. Patients with ART experi-
ence and no prior TDF exposure were less likely to discontinue
TDF therapy, compared with ART-naive individuals (HR, 0.78
[95% CI, .71–.86]), whereas patients with ART experience in-
cluding previous TDF therapy showed an increased likelihood
of discontinuing TDF therapy (HR, 1.24 [95% CI, 1.07–1.4]).
A higher CD4+ T-cell count (HR, 0.99 per 50 cells/mm3 in-
crease [95% CI, .98–.99]), coadministration of TDF with an
NNRTI (HR, 0.56 [95% CI, .50–.63]), and a previous AIDS-
deﬁning event (HR, 0.83 [95% CI, .77–.90]) were associated
with a decreased likelihood of discontinuing TDF therapy (Sup-
plementary Table 1).
Table 1. Characteristics of Patients in the United Kingdom
Collaborative HIV Cohort Study Who Were Exposed to Tenofovir
Disoproxil Fumarate (TDF) for ≥6 Months
Characteristic Value
Male sex 10 550 (81.1)
Ethnicity
White 8300 (63.8)
Black 3026 (23.3)
Other/unknown 1681 (12.9)
Route of HIV exposure
Homosexual/bisexual sex 8236 (63.3)
Heterosexual sex 3713 (28.6)
IDU 356 (2.7)
Other/unknown 702 (5.4)
Calendar year
1999–2003 2482 (19.1)
2004–2007 3992 (30.7)
2008–2010 6533 (50.2)
Previous exposure to TDF 603 (4.6)
ART naive 4466 (34.4)
ARV class
PI based (no ATZ) 2690 (20.7)
PI based (with ATZ) 1329 (10.2)
NNRTI based 7098 (54.6)
Other 1890 (14.5)
Previous AIDS-defining event 3053 (23.5)
HBV status
Negative 8412 (64.7)
Positive 599 (4.6)
Not tested 3996 (30.7)
HCV status
Negative 8619 (66.3)
Positive 730 (5.6)
Not tested 3658 (28.1)
eGFR
<60 mL/min/1.73 m2 166 (1.4)
60–74 mL/min/1.73 m2 985 (8.5)
75–89 mL/min/1.73 m2 2572 (22.1)
≥90 mL/min/1.73 m2 7898 (68.0)
Age, y 40 (34–46)
CD4+ T-cell count, cells/mm3 303 (190–482)
HIV load, log10 copies/mL 2.9 (1.7–4.7)
Data are no. (%) of patients or median value (interquartile range) and were
recorded at the start of TDF therapy.
Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral; ATZ, atazanavir;
eGFR, estimate glomerular filtration rate; HBV, hepatitis B virus; HCV,
hepatitis C virus; HIV, human immunodeficiency virus; IDU, injection drug
use; PI, protease inhibitor; NNRTI, nonnucleoside reverse-transcriptase
inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor.
a Data are for 11 621 patients with eGFR measure available in the 6 months
preceding TDF therapy.
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Changes in eGFR Before Initiation of, During, and After
Discontinuation of TDF Therapy
Of 3088 patients who discontinued TDF therapy, 834 (27.0%)
had sufﬁcient follow-up time and creatinine data to be included
in analyses of eGFR slopes. Those included were more likely to
be white (P < .0001), to be men who have sex with men
(P < .0001), to have higher CD4+ T-cell counts (P < .0001), to
have lower viral loads (P < .0001), to be cART naive at the
start of TDF therapy (P < .0001), to have started TDF therapy
in an earlier year (P < .0001), and to have experienced a previ-
ous AIDS-deﬁning event (P = .0003).
The median follow-up durations before initiation of, during,
and after discontinuation of TDF therapy were 5.8 years (IQR,
3.2–7.2 years), 2.4 years (IQR, 1.4–3.9 years), and 2.2 years
(IQR, 1.2–3.8 years). Slopes before initiation of, during, and
after discontinuation of TDF therapy are given in Table 2. Be-
fore TDF exposure, a small decrease in the eGFR of −0.9 mL/
minute/1.73 m2/year (95% CI, −1.6 to −.2) was seen in all pa-
tients, with a steeper decrease of −3.1 mL/minute/1.73 m2/year
(95% CI, −4.6 to −1.7) during TDF exposure (P = .007), com-
pared with mean slopes of −0.2 mL/minute/1.73 m2/year (95%
CI, −.6 to .3) and 0.3 mL/minute/1.73 m2/year (95% CI, .1–.5)
before and during TDF exposure, respectively, among 5669 in-
dividuals fulﬁlling the same inclusion criteria who did not dis-
continue TDF treatment. In patients who discontinued TDF
therapy, the mean eGFR increased after discontinuation (0.8
mL/minute/1.73 m2/year [95% CI, .1–1.5]). During the ﬁrst 3
months following initiation and discontinuation, there were
steep decreases and increases in mean slopes (−15.7 mL/
minute/1.73 m2/year [95% CI, −20.5 to −10.9]) and 12.5 mL/
minute/1.73 m2/year [95%CI, 8.9–16.1], respectively). When
slopes were stratiﬁed by baseline eGFR, those with an eGFR
of <60 mL/minute/1.73 m2 had experienced greater decline be-
fore TDF exposure. During TDF exposure, they experienced
smaller declines in the eGFR in the ﬁrst 3 months (−2.5 mL/mi-
nute/1.73 m2/year [95% CI, −17.1 to 12.1]; P = .32) compared
with those with higher eGFRs and somewhat greater declines
after this point (−8.3 mL/minute/1.73 m2/year [95% CI,
−18.1 to 1.5]; P = .43). Recovery appeared greater immediately
following discontinuation of TDF therapy (23.8 mL/minute/
1.73 m2/year [95% CI, 8.5–39.0]; P = .025), but there were no
differences in long-term slopes after discontinuation.
eGFR Recovery
Of 834 patients who discontinued TDF therapy with sufﬁcient
follow-up to assess recovery, 601 (72.1%) experienced a decline
in the eGFR during TDF exposure. Median eGFRs at start and
stop of TDF therapy were 94 mL/minute/1.73 m2 (IQR, 81–
108) and 77 mL/minute/1.73 m2 (IQR, 57–94), respectively. A
total of 85 (27.1%) of 314 patients with and 147 (51.2%) of 287
without a preexisting decline in the eGFR did not experience a
recovery in the GFR after discontinuing TDF therapy. For patients
in whom eGFR recovery was incomplete, 45 (20.1%), 40 (17.9%),
54 (24.1%), and 85 (37.9%) had an eGFR of ≥90, 75–89, 60–74,
and <60 mL/minute/1.73 m2 at the time TDF therapy was discon-
tinued (8 had an unknown eGFR at discontinuation). The median
time to recovery was 1.3 years (95% CI, 1.0–1.9) after discontin-
uation of TDF therapy, but recovery may have continued out to 5
years (Figure 2). The median eGFR was signiﬁcantly higher at
baseline (97 mL/minute/1.73 m2 [IQR, 86–110] vs 92 mL/mi-
nute/1.73 m2 [IQR, 77–106]; P≤ .0001) and lower at TDF therapy
discontinuation (66 mL/minute/1.73 m2 [IQR, 52–86] vs 82 mL/
minute/1.73 m2 [IQR, 64–97]; P < .0001) in patients with incom-
plete recovery. A total of 150 individuals (25.0%) were not receiv-
ing cART immediately following discontinuing TDF therapy,
including 22.4% with incomplete recovery of the eGFR and
26.6% with full recovery the eGFR. Approximately 59% of those
who either did or did not have complete recovery of the eGFR
were receiving a regimen containing a PI following discontinua-
tion of TDF therapy (P = .95), with approximately 16% in both
groups receiving atazanavir (P = .99). Whereas 21% of those
who experienced eGFR recovery received a NNRTI as part of
their cART regimen, 31% of those in whom the eGFR did not re-
cover received a NNRTI (P = .006).
Table 2. Estimated Glomerular Filtration Rate (eGFR) Slopes Before Initiation of, During, and After Discontinuation of Tenofovir
Disoproxil Fumarate (TDF) Exposure
Interval, Relative to TDF
Exposure Overall (n = 834)
By Baseline eGFR
<60 mL/min/1.73 m2
(n = 24)
60–89 mL/min/1.73 m2
(n = 322)
≥90 mL/min/1.73 m2
(n = 477)
Before initiation −0.9 (−1.6 to −0.2) −5.2 (−8.4 to −2.0) −1.4 (−2.2 to −0.5) −0.4 (−1.5 to 0.6)
During
≤3 mo −15.7 (−20.5 to −10.9) −2.5 (−17.1 to 12.1) −16.9 (−27.0 to −6.8) −15.3 (−19.9 to −10.7)
>3 mo −3.1 (−4.6 to −1.7) −8.3 (−18.1 to 1.5) −2.6 (−5.5 to 0.4) −3.3 (−4.8 to −1.8)
After discontinuation
≤3 mo 12.5 (8.9–16.1) 23.8 (8.5–39.0) 15.8 (10.0–21.6) 9.5 (4.7–14.3)
>3 mo 0.8 (0.1–1.5) −0.4 (−6.4 to 5.7) 0.3 (−0.8 to 1.4) 1.2 (0.12–2.1)
Data are mean values (95% confidence intervals) from a piecewise linear regression model.
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A lower eGFR at discontinuation of TDF therapy and a high-
er eGFR at initiation of TDF therapy were independently asso-
ciated with an increased odds of incomplete recovery at 6
months (Table 3). Longer TDF exposure was also associated
with an increased odds of incomplete recovery. Receiving a
PI-based regimen (vs an NNRTI-based regimen) at the start
of the TDF episode was associated with a decreased odds of ex-
periencing incomplete recovery. Similar results were obtained
when recovery was assessed at 12 or 24 months and when strat-
iﬁed by baseline eGFR (ie, < 90 vs ≥90 mL/minute/1.73 m2;
data not shown).
In 580 patients who discontinued TDF therapy with an un-
detectable viral load, mean eGFR slopes before initiation of,
during, and after discontinuation of TDF therapy were similar
to those seen in the whole group (−0.5 mL/minute/1.73 m2/
year before initiation of therapy [95% CI −1.2 to .1]), −3.4 mL/
minute/1.73 m2/year during therapy [95% CI, −5.2 to −1.6],
and 0.9 mL/minute/1.73 m2/year after discontinuation of ther-
apy [95% CI, .2–1.7]) and 41.2% of those with a decline in the
eGFR did not recover the eGFR during follow-up. Factors asso-
ciated with increased likelihood of incomplete recovery in this
group were similar to those described above; higher eGFR at
TDF initiation, lower eGFR at TDF discontinuation and longer
time on TDF. Reduced odds of incomplete recovery were again
observed when starting a PI-based regimen with TDF (data not
shown). Varying the choice of cutoff for deﬁning recovery to
10% and 15% meant that only 27.8% and 7% of individuals, re-
spectively, experienced incomplete eGFR recovery. At a 10%
cutoff, the factors associated with incomplete recovery re-
mained unchanged. At a 15% cutoff, only eGFRs at initiation
and discontinuation of TDF therapy were associated with in-
complete recovery at 6 months (results not shown).
DISCUSSION
In this large cohort of predominately white, HIV-infected men,
approximately one quarter of patients discontinued TDF ther-
apy after an exposure duration of at least 6 months. An acceler-
ated decline in the eGFR was observed during TDF exposure,
with substantial recovery in the ﬁrst 3 months after discontin-
uation of TDF. Nonetheless, 38% of patients did not experience
a recovery in the eGFR to within 5% of the baseline eGFR. An
eGFR of <75 mL/minute/1.73 m2 at the start of TDF therapy
was associated with an increased risk of discontinuing TDF
therapy, whereas an eGFR of <90 mL/minute/1.73 m2 at the
time of discontinuation was associated with an increased risk
of incomplete reversibility, as was longer exposure to TDF.
These data support renal function monitoring before and dur-
ing TDF exposure, and they caution against continued TDF ex-
posure in patient with or approaching CKD.
Underlying mechanisms of TDF toxicity have not been fully
elucidated. Tenofovir is renally excreted by both glomerular ﬁl-
tration and active tubular secretion. In the proximal renal tu-
bules, TDF is transported across the basolateral membrane via
human organic ion transporters 1 and 3 [29] and across the api-
cal membrane via multidrug-resistant protein 2 (MRP2) and
MRP4 [30]. Tenofovir toxicity has been linked to an increased
plasma drug concentration [31], and therefore mechanisms that
interfere with tenofovir excretion may increase the risk of tox-
icity. A low GFR will cause impaired TDF ﬁltration; the result-
ing increased plasma concentrations will promote active tubular
excretion. Polymorphisms in genes such as ABCC4 (which en-
codes MRP4), ABCC2 (which encodes MRP2), and ABCC10
(which encodes MRP7) are thought to lead to altered TDF
handling and intracellular accumulation of TDF [32]. Increased
Figure 2. Kaplan-Meier plot showing the cumulative proportion of individuals discontinuing tenofovir disoproxil fumarate (TDF) therapy following a de-
cline in the estimated glomerular ﬁltration rate (eGFR) that experienced eGFR recovery following discontinuation.
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intracellular TDF concentrations are postulated to cause mito-
chondrial toxicity, with features such as enlargement, depletion,
and dysmorphic mitochondrial changes seen in severe cases of
TDF-induced proximal tubulopathy [33]. Increases in TDF
plasma levels of approximately 20%–30%may also occur during
coadministration of TDF with a boosted PI [34]. Clinically, this
combination has been associated with worse renal outcomes
than TDF and a non-PI containing regimen [35–37]. Proposed
mechanisms include increased absorption of TDF via PI-related
inhibition of P-glycoprotein [38] or ritonavir-inhibited secre-
tion of TDF via MRP2 [39].
We observed an accelerated decline in the eGFR during TDF
therapy in all strata of eGFRs, a phenomenon seen in other
studies [40, 41]. The rapid changes in eGFR seen in the
3-month period between the start and discontinuation of
TDF therapy has been noted previously [21, 41]. In part, this
may be explained by residual tenofovir exposure or coadminis-
tered drugs inhibiting tubular creatinine excretion, although we
Table 3. Results of Univariable and Multivariable Logistic Regression Modeling to Determine Factors Associated With Incomplete
Recovery of the Estimated Glomerular Filtration Rate (eGFR) 6 Months After Discontinuation of Disoproxil Fumarate (TDF)
Factor
Univariable Multivariable
OR (95% CI) P OR 95% CI P
Age at initiation of TDF therapy (per 10 y increase) 1.13 (.95–1.34) .17 1.00 (.80–1.24) .57
Sex
Male 1.00 1.00
Female 0.67 (.43–1.03) .070 0.95 (.52–1.74) .87
Ethnicity
White 1.00 1.00
Black 0.59 (.38–.92) .020 0.82 (.45–1.52) .53
Other/unknown 1.00 (.57–1.76) .99 1.06 (.57–1.96) .85
Route of HIV exposure
Homosexual/bisexual sex 1.00
Heterosexual sex 0.75 (.51–1.10) .14 . . .
IDU 0.63 (.29–1.34) .29 . . .
Other/unknown 1.00 (.32–3.11) 1.00 . . .
ART naive at initiation of TDF therapy
No 1.00 . . .
Yes 0.93 (.55–1.57) .78 . . .
Regimen class at initiation of TDF therapy
NNRTI 1.00 1.00
PI 0.70 (.48–1.02) .066 0.60 (.39–.91) .018
Other 0.75 (.49–1.14) .18 0.69 (.43–1.11) .13
CD4 count at TDF stop (per 50 cells/mm3 increase) 1.01 (.98–1.05) .37 . . .
Undetectable viral load at discontinuation of TDF therapy
No 1.00 1.00
Yes 1.39 (.93–2.04) .087 0.96 (.63–1.48) .86
eGFR
At initiation of TDF therapy
≥90 mL/min/1.73 m2 1.00 1.00
75–90 mL/min/1.73 m2 1.10 (.74–1.64) .65 0.47 (.28–.78) .004
60–74 mL/min/1.73 m2 0.61 (.38–.99) .046 0.14 (.07–.27) <.0001
<60 mL/min/1.73 m2 0.24 (.08–.69) .008 0.04 (.01–.15) <.0001
At discontinuation of TDF therapy
≥90 mL/min/1.73 m2 1.00 1.00
75–90 mL/min/1.73 m2 1.59 (1.02–2.51) .043 2.18 (1.31–3.62) .003
60–74 mL/min/1.73 m2 2.38 (1.49–3.80) .0003 4.81 (2.61–8.89) <.0001
<60 mL/min/1.73 m2 2.96 (1.89–4.65) <.0001 13.18 (6.29–27.6) <.0001
Duration of TDF therapy (per year increase) 1.20 (1.09–1.32) .0003 1.15 (1.03–1.28) .012
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; IDU, injection drug use; OR, odds ratio; NNRTI,
nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor.
eGFR Reversibility With TDF • JID 2014:210 (1 August) • 369
were unable to investigate this in the current study. When the
actual GFR was measured in a study of individuals receiving
cART who switched to TDF-based regimens, although the
eGFR declined, there was no change in the measured GFR
[42]. Beyond the initial 3 months, the average overall decline
in eGFR was modest (−3.1 mL/minute/1.73 m2/year). This is
consistent with previous studies that suggested that the clinical
magnitude of TDF-related renal decline was limited. A meta-
analysis of TDF-containing regimens versus non–TDF-contain-
ing regimens demonstrated a mean difference in creatinine
clearance between the 2 groups of only 3.92 mL/min (95% CI,
2.13–5.70) [40], and similarly, in a cohort study with a 10-year
follow-up duration, the cumulative eGFR loss attributable to
TDF after 4 years was only −3.09 mL/min/1.73 m2 [41] but
slightly greater than the decline seen within the large US cohort
(84% of whom were receiving TDF-based regimens) of −1.37
mL/min/1.73 m2 (95% CI, −2.02–.72) [25].
Adverse effects of tenofovir on the kidney are likely the result
of tubular injury. Following ischemic or toxic insult, renal tubu-
lar cells may undergo some recovery with reversibility of renal
tubular damage as demonstrated in animal models [31] and in
observational human studies [43]. In our cohort, approximately
40% of patients with a decline in the eGFR had incomplete
eGFR recovery after discontinuation of TDF therapy, the major-
ity (62%) of whom had an eGFR of <75 mL/minute/1.73 m2
when TDF therapy was discontinued. Persistently impaired
renal function following TDF discontinuation may reﬂect irre-
versible tenofovir-induced kidney damage or progression of un-
derlying CKD. Because the eGFR at the time TDF therapy was
discontinued was an important predictor of incomplete recov-
ery, the beneﬁts of continued TDF exposure should be reviewed
in patients with an eGFR of <90 mL/minute/1.73 m2, and dis-
continuation of TDF therapy should be considered before the
eGFR decreases to <60 mL/minute/1.73 m2 (ie, those with a de-
clining eGFR in the range of 60 to 75 mL/minute/1.73 m2).
We were surprised to note that a lower eGFR at the start of
TDF therapy was protective against incomplete recovery. Al-
though only small numbers of patients started with an eGFR
of < 60 mL/minute/1.73 m2, the trend toward a better recovery
with a lower eGFR suggests a real phenomenon. This may re-
ﬂect the ﬁndings in the Development of Antiretroviral Therapy
(DART) trial, in which those with a lower eGFR at baseline had
the greatest increase after starting treatment [44]. Alternatively,
low eGFRs have been linked to increased tenofovir concentra-
tions [45], and therefore withdrawal of a higher tenofovir con-
centration may allow better eGFR recovery. We feel it unlikely
to be due to a low threshold for discontinuation in individuals
with a decreased eGFR at initiation of TDF therapy, because on
the duration of TDF therapy was taken into account in the
analysis.
We observed higher levels of eGFR recovery following dis-
continuation of TDF therapy than those observed in previous
studies [20, 21]. This may be because of our deﬁnition of recov-
ery (which considered reductions of up to 5% from baseline);
because we included discontinuations for any cause, not just
suspected TDF toxicity; and because we took into account a de-
cline in the eGFR before TDF initiation. Using at least 2 consec-
utive values to deﬁne recovery suggests that our ﬁndings are
robust and that recovery of the eGFR following discontinuation
of TDF therapy is achievable in the majority of patients. Al-
though recovery was not complete in all cases, it has previously
been reported to continue out to 5–17 months [20–22].We saw
recovery up to 5 years out, which may reﬂect the longer follow-
up time available. Factors previously associated with greater im-
provements in eGFR following discontinuation of TDF therapy
included concomitant PI use [20], which was postulated to have
been due to the withdrawal of TDF at a higher tenofovir plasma
concentration; rapid decline of eGFR within the ﬁrst month of
TDF exposure [21]; and higher nadir and discontinuation CD4+
T-cell counts [22]. In our cohort, we were unable to replicate
these ﬁndings, with the exception of PI use. The latter may
have occurred because some patients who discontinued TDF
therapy switched from an NNRTI to a ritonavir-boosted PI, re-
sulting in enhanced inhibition of MATE-1–mediated tubular
creatinine secretion [46].
Strengths of this study include the use of a large HIV-positive
cohort; inclusion of patients who discontinued TDF therapy for
any reason, not just toxicity; and a prolonged follow-up dura-
tion. We took into account renal declines detected before initi-
ation of TDF therapy when assessing the reversibility of renal
decline and the variability of eGFR, allowing a 5% change
from baseline. The 5% change was intended to account for in-
traindividual variance in creatinine (reported to be between
4.2%–14.4% [47–49]), intraanalytic variance, and, therefore,
the calculated coefﬁcient of variance for MDRD and CKD-
Epi (4.7% [48] and 7.2% [50], respectively). Using a conserva-
tive estimate of variability of 5%, we found that the majority of
patients had a recovered eGFR, and sensitivity analysis allowing
for 10% and 15% variability unsurprisingly yielded further im-
provements in recovery rates.
A limitation of this study is the variable frequency of eGFR
measurements in this observational setting, with creatinine data
unavailable for a substantive section of the cohort. Infrequent
eGFR measurements will impact eGFR slopes estimated by linear
regression. However, use of a mixed-effects regression model to
account for within-subject variability and correlated data pro-
duced very similar results. The mean eGFR slope estimates before
initiation of, during, and after discontinuation of TDF therapy,
according to mixed-effects models, were −0.4 mL/minute/1.73
m2/year (95% CI, −.6 to −.2), −3.5 mL/minute/1.73 m2/year
(95% CI, −4.1 to −2.9), and 0.3 mL/minute/1.73 m2/year (95%
CI, −.0 to .6). A total of 262 individuals (43.6%) did not have a
recovery in the eGFR during follow-up, compared with 38.6% ac-
cording to linear regression models.
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We were unable to consider other factors associated with dis-
continuation of TDF therapy, such as nonadherence or HIV
drug resistance, or factors that may be associated with recovery,
such as cardiovascular and renal risk factors (diabetes, hyper-
tension, and proteinuria), a reliable indicator of muscle mass,
clinical and socioeconomic status, and the impact of loss to fol-
low-up. We cannot exclude the possibility that any observed
renal decline was due to other drugs, rather than to TDF. The
length of follow-up may not have allowed for maximum renal
recovery, and the lack of access to individual patient records
meant that those who stopped for renal toxicity could not be
deﬁned. However, when considering only those with an unde-
tectable viral load at discontinuation of TDF therapy, we did not
see any difference in our results.
In conclusion, for the majority of patients who discontinue
TDF therapy, recovery of the eGFR is achievable. Patients
with CKD who initiated TDF therapy were at risk of a further
decline in the eGFR, whereas ongoing TDF exposure increased
the risk of an incomplete eGFR recovery. This study supports
continued renal monitoring during exposure to TDF and cau-
tions against prolonged TDF exposure in individuals with a de-
clining eGFR.
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